MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue 4, 2015, Pages 426-434

  He, Song ^a   Zhang, De Chun ^b   Wei, Cheng ^a  

^a Ma anshan Municipal People's Hospital   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 101; MICRORNA 10A; MICRORNA 122; MICRORNA 122A; MICRORNA 125B; MICRORNA 126; MICRORNA 130B; MICRORNA 139; MICRORNA 141; MICRORNA 145; MICRORNA 148A; MICRORNA 15B; MICRORNA 16; MICRORNA 182; MICRORNA 183; MICRORNA 18A; MICRORNA 192; MICRORNA 198; MICRORNA 199A; MICRORNA 200C; MICRORNA 206; MICRORNA 221; MICRORNA 223; MICRORNA 26A; MICRORNA 500; MICRORNA 618; MICRORNA 650; MICRORNA 801; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER TISSUE; HUMAN; LIVER CELL CARCINOMA; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; CARCINOMA, HEPATOCELLULAR; DOWN REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; METASTASIS; PROGNOSIS; UPREGULATION;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; HUMANS; LIVER NEOPLASMS; MICRORNAS; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; UP-REGULATION;

EID: 84940899773     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.01.006     Document Type: Short Survey

References (104)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
3. Maluccio M., Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012, 62:394-399.
4. Schwartz M., Roayaie S., Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007, 4:424-432.
5. Poon R.T., Fan S.T. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004, 10:S39-S45.
6. Yuen M.F., Cheng C.C., Lauder I.J., et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000, 31:330-335.
7. Fukuda S., Itamoto T., Nakahara H., et al. Clinicopathologic features and prognostic factors of resected solitary small-sized hepatocellular carcinoma. Hepatogastroenterology 2005, 52:1163-1167.
8. Jelic S., Sotiropoulos G.C., ESMO Guidelines Working Group Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v59-v64.
9. Choi J., Park Y., Kim J.H., et al. Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma. Clin Biochem 2011, 44:1464-1468.
10. Collier J., Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998, 27:273-278.
11. Oka H., Tamori A., Kuroki T., et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19:61-66.
12. Abdalla M.A., Haj-Ahmad Y. Promising candidate urinary microRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer 2012, 3:19-31.
13. Shen Q., Fan J., Yang X.R., et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012, 13:817-826.
14. Morishita A., Masaki T. MicroRNAs in hepatocellular carcinoma. Hepatol Res 2014, [Epub ahead of print]. 10.1111/hepr.12386.
15. Qi J., Wang J., Katayama H., et al. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 2013, 60:135-142.
16. Xie Y., Yao Q., Butt A.M., et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther 2014, 15:1-8.
17. Zheng J.J., Yu F.J., Dong P.H., et al. Expression of miRNA-29b and its clinical significances in primary hepatic carcinoma. Zhonghua Yi Xue Za Zhi 2013, 93:888-891. [Article in Chinese].
18. Li L., Guo Z., Wang J., et al. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci 2012, 57:2910-2916.
19. Liu A.M., Yao T.J., Wang W., et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012, 2:e000825.
20. Bihrer V., Waidmann O., Friedrich-Rust M., et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011, 6:e26971.
21. Li L.M., Hu Z.B., Zhou Z.X., et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010, 70:9798-9807.
22. Gui J., Tian Y., Wen X., et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011, 120:183-193.
23. Zhou J., Yu L., Gao X., et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011, 29:4781-4788.
24. Li T., Yin J., Yuan L., et al. Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival. Oncol Rep 2014, 31:1699-1706.
25. Shen J., Wang A., Wang Q., et al. Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev 2013, 22:2364-2373.
26. Tomimaru Y., Eguchi H., Nagano H., et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012, 56:167-175.
27. El-Garem H., Ammer A., Shehab H., et al. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol 2014, 6:818-824.
28. Tan Y., Ge G., Pan T., et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One 2014, 9:e107986.
29. Liang Z., Gao Y., Shi W., et al. Expression and significance of microRNA-183 in hepatocellular carcinoma. ScientificWorldJournal 2013, 2013:381874.
30. Zhu H.T., Dong Q.Z., Sheng Y.Y., et al. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 2012, 7:e52393.
31. Fu Y., Wei X., Tang C., et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett 2013, 6:1811-1815.
32. Su Z.X., Zhao J., Rong Z.H., et al. Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol 2014, 9:47.
33. Dang Y.W., Chen G., Liao Y., et al. Expression of miR-191 and miR-221 in hepatocellular carcinoma and its clinical significance. Zhonghua Bing Li Xue Za Zhi 2013, 42:397-398. [Article in Chinese].
34. Gu H., Guo X., Zou L., et al. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem 2013, 375:23-30.
35. Zheng J., Dong P., Gao S., Wang N., Yu F. High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma. Hepatogastroenterology 2013, 60:549-552.
36. Zhan M.X., Li Y., Hu B.S., et al. Expression of serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular carcinoma and its clinical significance. Zhonghua Yi Xue Za Zhi 2013, 93:1830-1832. [Article in Chinese].
37. Dang Y., Luo D., Rong M., et al. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One 2013, 8:e61054.
38. Chen P., Zhao X., Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem 2013, 383:49-58.
39. Rong M., He R., Dang Y., et al. Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci 2014, 119:19-24.
40. Yunqiao L., Vanke H., Jun X., et al. MicroRNA-206, down-regulated in hepatocellular carcinoma, suppresses cell proliferation and promotes apoptosis. Hepatogastroenterology 2014, 61:1302-1307.
41. Huang X.H., Wang Q., Chen J.S., et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 2009, 39:786-794.
42. Ge W., Yu D.C., Li Q.G., et al. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. Clin Lab 2014, 60:427-434.
43. Li J., Wang Y., Yu W., et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011, 406:70-73.
44. Zhou L., He J., Zhang Y. MicroRNA-22 expression in hepatocellular carcinoma and its correlation with ezrin protein. J Int Med Res 2013, 41:1009-1016.
45. Pan L., Huang S., He R., et al. Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues. Eur J Med Res 2014, 19:68.
46. Köberle V., Kronenberger B., Pleli T., et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013, 49:3442-3449.
47. Yu L., Zhang J., Guo X., et al. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma. Cancer Epidemiol 2014, 38:408-413.
48. Li W., Xie L., He X., et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008, 123:1616-1622.
49. Xiao F., Zhang W., Zhou L., et al. microRNA-200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6. Oncol Rep 2013, 30:2203-2210.
50. Zhan M., Li Y., Hu B., et al. Serum MicroRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2014, 25:1279-1287.
51. Chen L., Jiang M., Yuan W., et al. miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 2012, 25:156-161.
52. Han Z.B., Chen H.Y., Fan J.W., et al. Expression and survival prediction of microRNA-155 in hepatocellular carcinoma after liver transplantation. Zhonghua Yi Xue Za Zhi 2013, 93:884-887. [Article in Chinese].
53. Han Z.B., Chen H.Y., Fan J.W., et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 2012, 138:153-161.
54. Zhi Q., Zhu J., Guo X., et al. Metastasis-related miR-185 is a potential prognostic biomarker for hepatocellular carcinoma in early stage. Biomed Pharmacother 2013, 67:393-398.
55. Han Z.B., Zhong L., Teng M.J., et al. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 2012, 6:445-457.
56. Zhang Y., Guo X., Xiong L., et al. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett 2012, 586:4362-4370.
57. Zhang Z., Zheng W., Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol 2014, 31:984.
58. Wang J., Li J., Wang X., et al. Downregulation of microRNA-214 and overexpression of FGFR-1 contribute to hepatocellular carcinoma metastasis. Biochem Biophys Res Commun 2013, 439:47-53.
59. Wang J., Li J., Shen J., et al. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012, 12:227.
60. Yoon S.O., Chun S.M., Han E.H., et al. Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Hum Pathol 2011, 42:1391-1400.
61. Coulouarn C., Factor V.M., Andersen J.B., et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28:3526-3536.
62. Salvi A., Abeni E., Portolani N., et al. Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC. Int J Oncol 2013, 42:391-402.
63. Gao P., Wong C.C., Tung E.K., et al. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 2011, 54:1177-1184.
64. Pineau P., Volinia S., McJunkin K., et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 2010, 107:264-269.
65. Wang X.W., Heegaard N.H., Orum H. MicroRNAs in liver disease. Gastroenterology 2012, 142:1431-1443.
66. Ryan B.M., Robles A.I., Harris C.C. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010, 10:389-402.
67. Ma X.P., Zhang T., Peng B., et al. Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. PLoS One 2013, 8:e79584.
68. Wang B.S., Liu Z., Xu W.X., et al. Functional polymorphisms in microRNAs and susceptibility to liver cancer: a meta-analysis and meta-regression. Genet Mol Res 2014, 13:5426-5440.
69. Wang Z., Zhang L., Shi X., et al. Association between two common polymorphisms and risk of hepatocellular carcinoma: evidence from an updated meta-analysis. Biomed Res Int 2014, 2014:468605.
70. Lee D.Y., Deng Z., Wang C.H., et al. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 2007, 104:20350-20355.
71. An J., Liu J., Liu L., et al. A genetic variant in primary miR-378 is associated with risk and prognosis of hepatocellular carcinoma in a Chinese population. PLoS One 2014, 9:e93707.
72. Liu Y., Xie K., Wen J., et al. A genetic variant in microRNA-122 regulatory region confers risk for chronic hepatitis B virus infection and hepatocellular carcinoma in Han Chinese. J Med Virol 2014, 86:1669-1674.
73. Son M.S., Jang M.J., Jeon Y.J., et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene 2013, 524:156-160.
74. Zhou B., Dong L.P., Jing X.Y., et al. Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population. Tumour Biol 2014, 35:7775-7780.
75. Xu T., Zhu Y., Wei Q.K., et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008, 29:2126-2131.
76. Liu Y., Zhang Y., Wen J., et al. A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One 2012, 7:e32230.
77. Xie K., Liu J., Zhu L., et al. A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol 2013, 37:998-1002.
78. Wang X.H., Wang F.R., Tang Y.F., et al. Association of miR-149C>T and miR-499A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population. Genet Mol Res 2014, 13:5048-5054.
79. Ma Y., Wang R., Zhang J., et al. Identification of miR-423 and miR-499 polymorphisms on affecting the risk of hepatocellular carcinoma in a large-scale population. Genet Test Mol Biomarkers 2014, 18:516-524.
80. Chu Y.H., Hsieh M.J., Chiou H.L., et al. MicroRNA gene polymorphisms and environmental factors increase patient susceptibility to hepatocellular carcinoma. PLoS One 2014, 9:e89930.
81. Xiang Y., Fan S., Cao J., et al. Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population. Mol Biol Rep 2012, 39:7019-7023.
82. Shan Y.F., Huang Y.H., Chen Z.K., et al. miR-499A>G rs3746444 and miR-146aG>C expression and hepatocellular carcinoma risk in the Chinese population. Genet Mol Res 2013, 12:5365-5371.
83. Zou H.Z., Zhao Y.Q. Positive association between miR-499A>G and hepatocellular carcinoma risk in a Chinese population. Asian Pac J Cancer Prev 2013, 14:1769-1772.
84. Kim W.H., Min K.T., Jeon Y.J., et al. Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene 2012, 504:92-97.
85. Akkiz H., Bayram S., Bekar A., et al. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. J Viral Hepat 2011, 18:e399-e407.
86. Qi P., Dou T.H., Geng L., et al. Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum Immunol 2010, 71:621-626.
87. Zhang J., Wang R., Ma Y.Y., et al. Association between single nucleotide polymorphisms in miRNA196a-2 and miRNA146a and susceptibility to hepatocellular carcinoma in a Chinese population. Asian Pac J Cancer Prev 2013, 14:6427-6431.
88. Grady W.M., Tewari M. The next thing in prognostic molecular markers: microRNA signatures of cancer. Gut 2010, 59:706-708.
89. Liu L., An J., Liu J., et al. Potentially functional genetic variants in microRNA processing genes and risk of HBV-related hepatocellular carcinoma. Mol Carcinog 2013, 52:E148-E154.
90. Kim H.Y., Yoon J.H., Lee H.S., et al. MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. J Med Virol 2014, 86:446-453.
91. Chen S., He Y., Ding J., et al. An insertion/deletion polymorphism in the 3' untranslated region of beta-transducin repeat-containing protein (betaTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem Biophys Res Commun 2010, 391:552-556.
92. Guo Z., Wu C., Wang X., et al. A polymorphism at the miR-502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome. Int J Cancer 2012, 131:1318-1322.
93. Gao Y., He Y., Ding J., et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 2009, 30:2064-2069.
94. Kwak M.S., Lee D.H., Cho Y., et al. Association of polymorphism in pri-microRNAs-371-372-373 with the occurrence of hepatocellular carcinoma in hepatitis B virus infected patients. PLoS One 2012, 7:e41983.
95. Li Z., Guo Y., Zhou L., et al. Association of a functional RAD52 genetic variant locating in a miRNA binding site with risk of HBV-related hepatocellular carcinoma. Mol Carcinog 2014, [Epub ahead of print]. 10.1002/mc.22156.
96. Qi F., Huang M., Pan Y., et al. A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese. PLoS One 2014, 9:e85394.
97. Zhang L.S., Liang W.B., Gao L.B., et al. Association between pri-miR-218 polymorphism and risk of hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol 2012, 31:761-765.
98. Zhou C., Yu Q., Chen L., et al. A miR-1231 binding site polymorphism in the 3'UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility. Gene 2012, 507:95-98.
99. Wang Z., Wu J., Zhang G., et al. Associations of miR-499 and miR-34b/c polymorphisms with susceptibility to hepatocellular carcinoma: an evidence-based evaluation. Gastroenterol Res Pract 2013, 2013:719202.
100. Xu Y., Liu L., Liu J., et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 2011, 128:412-417.
101. Yu Q., Zhou C.X., Chen N.S., et al. A polymorphism within ErbB4 is associated with risk for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2012, 18:383-387.
102. Han Y., Pu R., Han X., et al. Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk. Liver Int 2014, 34:728-736.
103. Tao T., Chen S., Xu B., et al. Association between hsa-miR-34b/c rs4938723T>C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls. Chin J Cancer Res 2014, 26:315-322.
104. Han Y., Pu R., Han X., et al. Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One 2013, 8:e58564.